| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Angeloylgomisin Q is a dibenzocyclooctadiene lignan, a class of compounds known for various biological activities including neuroprotective effects. The compound has the potential for Alzheimer's disease research. As a lignan from Schisandra species, it may interact with targets involved in neurodegeneration, including pathways related to oxidative stress, inflammation, and cognitive function. Schisandra lignans are known for their adaptogenic and neuroprotective properties. The compound's potential for Alzheimer's disease research suggests it may target pathways involved in amyloid-beta aggregation, tau phosphorylation, or neuroinflammation. Further research is needed to identify its specific molecular targets.
|
|---|---|
| ln Vitro |
In vitro studies of Angeloylgomisin Q are limited, as the compound is a relatively new discovery. It is a dibenzocyclooctadiene lignan from the stems of Schisandra sphaerandra. The compound has been characterized using analytical chemistry methods including HPLC. Its potential for Alzheimer's disease research has been identified. As a lignan, it may exhibit antioxidant, anti-inflammatory, and neuroprotective activities similar to other Schisandra lignans. These in vitro findings support its potential for further investigation in neurodegenerative disease research. Further studies are needed to fully characterize its biological activities and mechanisms of action.
|
| ln Vivo |
In vivo studies of Angeloylgomisin Q are not well documented, as the compound is a relatively new discovery. Its potential for Alzheimer's disease research suggests that in vivo evaluation in animal models of Alzheimer's disease would be warranted. As a lignan from Schisandra chinensis, it may exhibit similar in vivo effects to other Schisandra lignans, including neuroprotective and cognitive-enhancing properties. However, comprehensive in vivo studies specifically targeting Angeloylgomisin Q are not well documented in the available literature. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Angeloylgomisin Q are not well documented, as the compound is a relatively new discovery. Its potential for Alzheimer's disease research suggests that assays targeting Alzheimer's-related pathways would be relevant. These could include assays measuring inhibition of acetylcholinesterase, beta-secretase, or amyloid-beta aggregation. Antioxidant activity could be assessed using cell-free systems such as DPPH radical scavenging assays. Anti-inflammatory activity could be evaluated by measuring inhibition of pro-inflammatory mediators. All assays would be performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Angeloylgomisin Q would involve culturing neuronal cells to evaluate its neuroprotective effects. Cells would be treated with varying concentrations of the compound and then exposed to neurotoxic insults such as amyloid-beta, oxidative stress, or excitotoxicity. Cell viability would be assessed using MTT or similar colorimetric assays. Markers of neurodegeneration, oxidative stress, and inflammation would be measured. The compound's effects on neuronal survival and function would be evaluated. All experiments would be performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Angeloylgomisin Q would be conducted to evaluate its potential for Alzheimer's disease research. Animal models of Alzheimer's disease such as transgenic mice expressing amyloid-beta or tau would be used. Animals would be administered the compound orally or by other routes, and cognitive function would be assessed using behavioral tests such as Morris water maze or novel object recognition. Parameters assessed would include amyloid-beta burden, tau pathology, neuroinflammation, and synaptic markers. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Angeloylgomisin Q reflect its nature as a lignan compound. It has a molecular weight of 530.61 and the molecular formula C29H38O9. The compound appears as a white crystalline powder and has a purity of 98% by HPLC. As a lignan, it may have moderate lipophilicity that facilitates absorption and distribution. The compound is expected to be metabolized through standard xenobiotic pathways in the liver. Complete pharmacokinetic profiling including half-life, clearance, volume of distribution, and bioavailability would require further systematic studies using appropriate analytical methods such as high-performance liquid chromatography-mass spectrometry.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Angeloylgomisin Q has been evaluated in the context of its use as a research chemical. As a natural lignan from Schisandra chinensis, it is expected to have a favorable safety profile at research concentrations. Schisandra lignans are traditionally used in herbal medicine and are generally considered safe. However, as with all research chemicals, proper handling procedures including use of personal protective equipment are recommended. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications.
|
| References | |
| Additional Infomation |
Schisandra chinensis is reported to contain angelicin Q; related data has been reported. See also: Schisandra chinensis fruit (partial).
Angeloylgomisin Q (CAS# 72561-28-5) is also known as Angeloylgomisin Q. It has the molecular formula C29H38O9 and a molecular weight of 530.61. The compound is a new dibenzocyclooctadiene lignan that can be found in Schisandra chinensis stems. It is also found in the stems of Schisandra sphaerandra. Angeloylgomisin Q has the potential for Alzheimer's disease research. The compound is a phenylpropanoid and appears as a white crystalline powder. It has a purity of 98% by HPLC and is intended for research use only. |
| Molecular Formula |
C29H38O9
|
|---|---|
| Molecular Weight |
530.61
|
| Exact Mass |
530.251
|
| CAS # |
72561-28-5
|
| PubChem CID |
14992071
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
638.0±55.0 °C at 760 mmHg
|
| Flash Point |
201.6±25.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.564
|
| LogP |
5.47
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
38
|
| Complexity |
818
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C/C=C(/C)\C(=O)O[C@H]1C2=CC(=C(C(=C2C3=C(C(=C(C=C3C[C@@H]([C@]1(C)O)C)OC)OC)OC)OC)OC)OC
|
| InChi Key |
RHABJANPSGWEFC-MRFZJNLZSA-N
|
| InChi Code |
InChI=1S/C29H38O9/c1-11-15(2)28(30)38-27-18-14-20(33-6)24(35-8)26(37-10)22(18)21-17(12-16(3)29(27,4)31)13-19(32-5)23(34-7)25(21)36-9/h11,13-14,16,27,31H,12H2,1-10H3/b15-11-/t16-,27-,29-/m0/s1
|
| Chemical Name |
[(8S,9S,10S)-9-hydroxy-3,4,5,14,15,16-hexamethoxy-9,10-dimethyl-8-tricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaenyl] (Z)-2-methylbut-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8846 mL | 9.4231 mL | 18.8462 mL | |
| 5 mM | 0.3769 mL | 1.8846 mL | 3.7692 mL | |
| 10 mM | 0.1885 mL | 0.9423 mL | 1.8846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
